Iovance Biotherapeutics, Inc. (0JDK.L)
USD 7.6
(-2.69%)
USD 7.6
(-2.69%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 195.73 Million USD | 19.1% |
| 2022 | 164.34 Million USD | 5.57% |
| 2021 | 155.67 Million USD | 39.04% |
| 2020 | 111.96 Million USD | 145.07% |
| 2019 | 45.68 Million USD | 212.31% |
| 2018 | 14.62 Million USD | 47.88% |
| 2017 | 9.89 Million USD | 99.11% |
| 2016 | 4.96 Million USD | 204.79% |
| 2015 | 1.63 Million USD | -1.93% |
| 2014 | 1.66 Million USD | -26.78% |
| 2013 | 2.26 Million USD | -80.0% |
| 2012 | 11.34 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 189.8 Million USD | -3.03% |
| 2024 Q2 | 195.78 Million USD | 3.15% |
| 2023 Q3 | 178.3 Million USD | -0.23% |
| 2023 Q1 | 157.88 Million USD | -3.93% |
| 2023 Q2 | 178.72 Million USD | 13.2% |
| 2023 FY | 195.73 Million USD | 19.1% |
| 2023 Q4 | 195.73 Million USD | 9.78% |
| 2022 Q4 | 164.34 Million USD | 7.99% |
| 2022 Q3 | 152.18 Million USD | 10.13% |
| 2022 Q2 | 138.18 Million USD | -7.42% |
| 2022 FY | 164.34 Million USD | 5.57% |
| 2022 Q1 | 149.25 Million USD | -4.12% |
| 2021 Q3 | 130.49 Million USD | 20.41% |
| 2021 Q4 | 155.67 Million USD | 19.29% |
| 2021 Q1 | 103.14 Million USD | -7.88% |
| 2021 FY | 155.67 Million USD | 39.04% |
| 2021 Q2 | 108.37 Million USD | 5.08% |
| 2020 Q3 | 70.45 Million USD | 18.89% |
| 2020 Q4 | 111.96 Million USD | 58.91% |
| 2020 FY | 111.96 Million USD | 145.07% |
| 2020 Q1 | 44.98 Million USD | -1.53% |
| 2020 Q2 | 59.25 Million USD | 31.73% |
| 2019 Q4 | 45.68 Million USD | 12.29% |
| 2019 Q3 | 40.68 Million USD | 5.66% |
| 2019 Q2 | 38.5 Million USD | 44.91% |
| 2019 Q1 | 26.57 Million USD | 84.54% |
| 2019 FY | 45.68 Million USD | 212.31% |
| 2018 Q4 | 14.39 Million USD | -13.65% |
| 2018 Q3 | 16.67 Million USD | 17.57% |
| 2018 Q2 | 14.18 Million USD | -3.46% |
| 2018 Q1 | 14.69 Million USD | 53.1% |
| 2018 FY | 14.62 Million USD | 47.88% |
| 2017 Q4 | 9.59 Million USD | 12.5% |
| 2017 FY | 9.89 Million USD | 99.11% |
| 2017 Q3 | 8.52 Million USD | -3.74% |
| 2017 Q1 | 5.5 Million USD | 10.77% |
| 2017 Q2 | 8.86 Million USD | 61.0% |
| 2016 Q3 | 3.19 Million USD | -30.66% |
| 2016 FY | 4.96 Million USD | 204.79% |
| 2016 Q4 | 4.96 Million USD | 55.54% |
| 2016 Q2 | 4.6 Million USD | 151.69% |
| 2016 Q1 | 1.83 Million USD | 12.27% |
| 2015 Q2 | 1.86 Million USD | -2.33% |
| 2015 FY | 1.63 Million USD | -1.93% |
| 2015 Q3 | 2.85 Million USD | 52.99% |
| 2015 Q4 | 1.63 Million USD | -42.91% |
| 2015 Q1 | 1.91 Million USD | 14.96% |
| 2014 Q3 | 1.25 Million USD | 8.84% |
| 2014 Q4 | 1.66 Million USD | 32.04% |
| 2014 Q1 | 1.1 Million USD | -51.12% |
| 2014 Q2 | 1.15 Million USD | 4.23% |
| 2014 FY | 1.66 Million USD | -26.78% |
| 2013 FY | 2.26 Million USD | -80.0% |
| 2013 Q2 | 3.36 Million USD | -72.62% |
| 2013 Q1 | 12.3 Million USD | 8.44% |
| 2013 Q3 | 3.5 Million USD | 4.16% |
| 2013 Q4 | 2.26 Million USD | -35.31% |
| 2012 FY | 11.34 Million USD | 0.0% |
| 2012 Q4 | 11.34 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Editas Medicine, Inc. | 150.05 Million USD | -30.443% |
| Dynavax Technologies Corporation | 375.02 Million USD | 47.807% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | 59.845% |
| Perrigo Company plc | 6.04 Billion USD | 96.76% |
| Illumina, Inc. | 4.36 Billion USD | 95.517% |
| Thermo Fisher Scientific Inc. | 51.88 Billion USD | 99.623% |
| Walgreens Boots Alliance, Inc. | 68.85 Billion USD | 99.716% |
| IQVIA Holdings Inc. | 20.56 Billion USD | 99.048% |
| Heron Therapeutics, Inc. | 256.47 Million USD | 23.683% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 97.246% |
| Unity Biotechnology, Inc. | 37.29 Million USD | -424.879% |
| Waters Corporation | 3.47 Billion USD | 94.37% |
| Biogen Inc. | 12.04 Billion USD | 98.375% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | -137.451% |
| Evolus, Inc. | 209.68 Million USD | 6.652% |
| Adicet Bio, Inc. | 37.12 Million USD | -427.311% |
| Cara Therapeutics, Inc. | 68.75 Million USD | -184.673% |
| bluebird bio, Inc. | 424.62 Million USD | 53.903% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | 70.378% |
| FibroGen, Inc. | 585.72 Million USD | 66.582% |
| Agilent Technologies, Inc. | 4.91 Billion USD | 96.02% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -456.436% |
| Homology Medicines, Inc. | 118.53 Million USD | -65.134% |
| Geron Corporation | 146.12 Million USD | -33.951% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | 95.168% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | 68.312% |
| Myriad Genetics, Inc. | 312.9 Million USD | 37.444% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -875.228% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | 21.957% |
| Zoetis Inc. | 9.29 Billion USD | 97.894% |
| Abeona Therapeutics Inc. | 49.17 Million USD | -298.036% |
| Mettler-Toledo International Inc. | 3.5 Billion USD | 94.416% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | 89.644% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | 96.199% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | -304.042% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | 92.481% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | 26.063% |
| Verastem, Inc. | 71.18 Million USD | -174.971% |
| Nektar Therapeutics | 267.04 Million USD | 26.703% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | 50.728% |
| Aclaris Therapeutics, Inc. | 40.22 Million USD | -386.596% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | 91.862% |
| OPKO Health, Inc. | 622.47 Million USD | 68.555% |
| Exelixis, Inc. | 678.44 Million USD | 71.149% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | 80.799% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | -70.486% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -1461.656% |
| uniQure N.V. | 624.01 Million USD | 68.633% |
| Imunon, Inc. | 8.53 Million USD | -2194.586% |
| Blueprint Medicines Corporation | 918.64 Million USD | 78.693% |
| Insmed Incorporated | 1.66 Billion USD | 88.221% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | 88.133% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | -55.226% |
| TG Therapeutics, Inc. | 169.08 Million USD | -15.763% |
| Incyte Corporation | 1.59 Billion USD | 87.707% |
| Emergent BioSolutions Inc. | 1.18 Billion USD | 83.49% |